Eye Diseases Trachoma
Conditions
Interventions
S, F & E arm
Control
Sponsors
The Carter Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All districts in West Amhara that have completed five or more annual rounds of MDA with azithromycin and have been surveyed for impact will be eligible for inclusion into the study.
Exclusion criteria
Exclusion criteria: Districts where SAFE has been implemented for less than 5 years or where impact evaluations have showed prevalence of TF in children 1-9 years to be below 10% will not be included into the study. In the excluded districts, the SAFE strategy will be continued as per the WHO standards and national guidelines.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Prevalence of TF (trachomatous inflammation-follicular) in children ages 1-9 years;¿Prevalence of ocular Chlamydia infection in children aged 1-9 years;¿Prevalence of TS in people aged 15 years and abov | — |
Secondary
| Measure | Time frame |
|---|---|
| ¿ Prevalence of TI in children aged 1-9 years;¿ Prevalence of clean faces in children aged 1-9 years;¿ Prevalence of TS in people aged below 15 years;¿ Uptake of SAFE interventions at the individual and household level | — |
Countries
Ethiopia
Contacts
Public ContactStephanie Palmer
Program Development Coordinator, Trachoma
Outcome results
None listed